When was Atmo Biosciences founded?

Atmo Biosciences was founded in 2017 and raised its 1st funding round 2 years after it was founded.

Where is Atmo Biosciences located?

Atmo Biosciences is headquartered in Melbourne, Australia.

Who is the current CEO of Atmo Biosciences?

Malcolm Hebblewhite of Atmo Biosciences.

How many employees does Atmo Biosciences have?

As of Jul 01, 2024, the latest employee count at Atmo Biosciences is 27.

Is Atmo Biosciences a funded company?

Atmo Biosciences is a funded company, having raised a total of $7.01M across 4 funding rounds to date. The company's 1st funding round was a $***** Seed round, raised on Mar 2019.

When was the latest funding round of Atmo Biosciences?

Atmo Biosciences' latest funding was a $***** Series B round on Sep 25, 2023, with participation from 1 investor.

Where does Atmo Biosciences rank among its competitors?

Atmo Biosciences ranks 9th amongst 246 active competitors, of which 41 are funded. It stands 5th in terms of total funding among its competitors. The most recent competitor to raise funding was Atmo Biosciences, which secured an undisclosed amount in Sep, 2023.

Who are the top competitors of Atmo Biosciences?

Atmo Biosciences' top competitors include Roche, NVision Imaging Technologies and numares. Among them, Atmo Biosciences secured the most recent funding round in September, 2023.

Atmo Biosciences - 2026 Company Profile, Team, Funding & Competitors

Company Details

Atmo Biosciences is a spinoff of the RMIT University in Melbourne, Australia that is commercializing a swallowable gas sensor that can reliably profile and monitor intestinal gases such as hydrogen, carbon dioxide, oxygen, etc. in real time. The capsule seamlessly transmits the data to a smartphone. Atmo has partnered with Planet Innovation, a product development firm, to develop their technology as a diagnostic device for an array of gut disorders, from food nutrient malabsorption to colon cancer.

Website: www.atmobiosciences.com/
Email ID: *****@atmobiosciences.com

Key Metrics

Founded Year

2017

Location

Melbourne, Australia

Stage

Series B

Total Funding

$7.01M in 4 rounds

Latest Funding Round

Series B, Sep 25, 2023, $*****

Investors

Breakthrough Victoria & 3 more

Ranked

9^th among 246 active competitors

Employee Count

27 as on Jul 01, 2024

Similar Companies

Roche & 200 more

View Atmo Biosciences' full profile

Atmo Biosciences has raised a total funding of $7.01M over 4 rounds. Its first funding round was on Mar 2019. Its latest funding round was a Series B round on Sep 25, 2023 for $*****. 1 investor participated in its latest round. Atmo Biosciences has 4 institutional investors.

Here is the list of recent funding rounds of Atmo Biosciences:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Sep 25, 2023	6305844	Series B	7236275	2395704	8514714	6143973
Mar 30, 2023	7462090	Series B	2916560	7951552	6043325	Otsuka
Jun 2020	5333001	Seed	7611799	2732615	9073740	7879262

Access funding benchmarks and valuations. Sign up today!

View details of Atmo Biosciences's funding rounds and investors

The founders of Atmo Biosciences is Malcolm Hebblewhite. Malcolm Hebblewhite is the CEO of Atmo Biosciences.

Here are the details of Atmo Biosciences' key team members:

Malcolm Hebblewhite: CEO, President, Co-founder, Managing Director of Atmo Biosciences.

View details of Atmo Biosciences's Founder profiles and Board Members

Atmo Biosciences' employee count trend

Atmo Biosciences has 27 employees as of Jul 24. Here is Atmo Biosciences's employee count trend over the years:

Employee count trend for Atmo Biosciences

Uncover Atmo Biosciences' growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Atmo Biosciences include Roche, NVision Imaging Technologies and numares. Here is the list of Top 10 competitors of Atmo Biosciences, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Roche 1896, Basel (Switzerland), Public	Developer of pharmaceuticals and diagnostics kits	-	SoftBank Group, Capricorn Partners & 10 others	70/100
2nd	NVision Imaging Technologies 2015, Ulm (Germany), Series A	Provider of medical imaging by quantum technologies	$35M	Playground Global, Kreissparkasse Esslingen Nurtingen ... & 8 others	63/100
3rd	numares 2004, Regensburg (Germany), Series B	Developer of diagnostic tests using metabolomics and nuclear magnetic resonance spectroscopy	$26.8M	Bayern Kapital, Kfw & 2 others	57/100
4th	EKF 1990, Penarth (United Kingdom), Public	Develops point-of-care and laboratory blood analyzers	$179K	IBG Beteiligungsgesellschaft Sachsen-Anhalt, Octopus Investments ... & 2 others	57/100
5th	Microlife 1981, Taipei (Taiwan), Public	Portfolio of thermometers and blood pressure monitors	-	Morgan Stanley Private Equity Asia	55/100
6th	SonoSite 1986, Bothell (United States), Acquired	Point-of-care ultrasound solutions provider, empowering clinicians with advanced imaging	-	Europa	55/100
7th	Hangzhou Deshi Biotechnology 2016, Hangzhou (China), Public	Devices for HPV virus detection & RNA detection	$30.2M	Xiangjiang Liyuan Investment, Zijingang Capital ... & 8 others	55/100
8th	NanoDx 2010, Southborough (United States), Series C	Manufacturer of diagnostic medical equipment and tests	$30.1M	SKK, MedScience Ventures & 3 others	54/100
9th	Atmo Biosciences 2017, Melbourne (Australia), Series B	Swallowable sensors for profiling intestinal gases	$7.01M	Alium Capital, Plug and Play APAC & 2 others	53/100
10th	DiaSorin 1968, Saluggia (Italy), Public	Develops and commercializes reagent kits for in vitro diagnostics	-	Public Health Emergency, Eiffel Investment Group ... & 1 others	53/100